Welcome to the August edition of the Tocagen Newsletter. Some of our recent progress includes:
4 scientific papers published in prestigious journals
13 presentations given at major scientific conferences
Clinical investigators presented for the first time interim Toca 511 & Toca FC safety and promising survival data at leading medical conferences
Jamey Skillings, MD named as Chief Medical Officer
1st patient dosed in intravenous Toca 511 clinical trial
Please stay tuned for more updates and thank you for your continued support in our fight against cancer.
The Tocagen team.
Tocagen Scientific Journal Articles
Tocagen virologist, Amy Lin, Ph.D., published research as lead author in the Journal of Virology relating to the tumor selectivity of Toca 511. Read the abstract. Amy is also lead author on a publication regarding Tocagen’s vectors in Human Gene Therapy. Read the abstract.
Ryan Burnett, Ph.D., a product development scientist at Tocagen published as lead author an article on the practical considerations for neurosurgeons while handling Toca 511. Read the abstract.
Tiffany Huang, Ph.D., a cancer biologist at Tocagen published as lead author research showing synergistic efficacy of Toca 511 combined with temozolomide. Read the abstract.
Tocagen Science Presentations
Drs. Vogelbaum (Cleveland Clinic) and Aghi (UCSF) presented updated safety and promising survival data for Toca 511 at the American Association of Neurological Surgeons Annual Meeting. Read the news release.
Dr. Cloughesy (UCLA) presented safety and evidence of antitumor activity for Toca 511 at the Society for Neuro-Oncology 2013 Annual Meeting. Read the news release. Posters were also presented by Tocagen scientists including data supporting Toca 511 in combination with radiation and temozolomide.
Joan Robbins, Ph.D. head of cancer biology at Tocagen presented a Toca 511 clinical trials update at the American Society of Clinical Oncology (ASCO) 50th Annual Meeting. Read the abstract.
Toca 511 in metastatic colon cancer model: Tocagen scientist Maria E. Rodriguez-Aguirre presented a poster at the American Association for Cancer Research (AACR). Read the abstract. This research also helped Maria win department and overall awards at the 8th National University Student Scholarship Conference.
Tocagen’s head of R&D, Doug Jolly, Ph.D., and scientist Tiffany Huang, Ph.D. presented updates on Toca 511 & Toca FC at the 17th Annual Meeting of the American Society for Gene and Cell Therapy. Read the news release.
In The News
Tocagen appointed Jamey Skillings, MD as Chief Medical Officer to accelerate and expand our clinical programs. Read the news release.
The first patient was dosed in new study to evaluate intravenous delivery of Toca 511. This is a key step in the development of Toca 511 and creates a potential opportunity for use in additional cancer indications such as colorectal cancer. Read the news release.
Harry Gruber, MD, CEO of Tocagen was recently interviewed for a profile article that appeared on LinkedIn. Read the interview.
Tocagen highlighted in Nature Jobs article titled “Medical research: Gene-therapy reboot”. Read the article.
The National Brain Tumor Society published an update on Tocagen’s progress. Read the update.
The University of Washington published an article on their input into the design of the therapeutic gene in Toca 511. Read the article.
The San Diego Union Tribune published an article about Toca 511 titled “Brain Cancer Treatment Promising”. Read the article.
Tocagen CEO Harry Gruber, MD discusses cancer gene and immunotherapy on the Burrill Report Pod Cast. Listen to the pod cast.
Forward-Looking Statements: Tocagen makes forward-looking statements herein or in connection herewith that involve potential risks and uncertainties. These statements include statements regarding Tocagen’s expectations, hopes, beliefs, intentions, or strategies regarding the future. These forward statements also include statements regarding (i) the success of Tocagen’s anticipated research and development efforts, including pre-clinical studies and the timing of, the government regulation of, and degree of safety and efficacy in, clinical trials, and Tocagen’s future financial results, (ii) Tocagen’s future financing assumptions, (iii) Tocagen’s market position and the size and competitiveness of its market for its anticipated products and services, and (iv) Tocagen’s ability to develop future products and services. It is important to note that Tocagen’s actual results could differ materially from those in such forward-looking statements.
Neither this newsletter nor any link in this Newsletter to other information, including but not limited to videos prepared by 3rd parties, constitutes an offer or invitation for the sale or purchase of securities. The information set out herein and therein is preliminary and should not be relied upon for any purpose. Tocagen does not make any representation or warranty, express or implied, as to the accuracy or completeness of the information contained herein and therein shall not have any liability for such information.
